Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis

Area of Science:

• Infectious Diseases
• Virology
• Pharmacology

Background:

• Human Immunodeficiency Virus (HIV) remains a significant global health concern.
• Current pre-exposure prophylaxis (PrEP) options primarily involve daily oral medications.
• There is a need for long-acting, convenient HIV prevention strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of lenacapavir as a twice-yearly injectable for HIV PrEP.
• To assess lenacapavir's effectiveness in diverse populations at risk for HIV-1 acquisition.

Main Methods:

• Two large Phase III clinical trials were conducted.
• Lenacapavir was administered as a subcutaneous injection every six months.
• HIV incidence was compared to background rates and daily oral PrEP.

Main Results:

• Lenacapavir demonstrated significantly lower HIV incidence compared to background rates and daily oral PrEP.
• High adherence rates were observed with lenacapavir administration.
• The drug was generally well-tolerated, with most injection-site reactions being mild and decreasing over time.

Conclusions:

• Lenacapavir is the first twice-yearly long-acting injectable approved for HIV PrEP.
• It offers a potent, convenient, and effective option for HIV prevention across various populations.
• Lenacapavir represents a significant advancement in the PrEP landscape.